---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-26-000006"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:28:22.567696+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B

## Summary
- Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).
- INGREZZA Q4 sales $657.5M (+7% YoY); full year $2.51B (+9% YoY); 2026 guidance $2.7-2.8B.
- CRENESSITY Q4 sales $135.3M (vs $1.7M YoY); full year $301.2M; 2,048 new patient start forms in FY.
- GAAP diluted EPS Q4 $1.48 (vs $1.00); full year $4.67 (vs $3.29). Non-GAAP EPS Q4 $1.88 (vs $1.69).
- Cash & marketable securities $2.54B at Dec 31, 2025; R&D and SG&A guidance provided for 2026.

## SEC filing metadata
- accession: 0000914475-26-000006
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447526000006/0000914475-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447526000006/nbix-20260211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-26-000006
- JSON: https://secwatch.observer/filing/0000914475-26-000006.json
- Plain text: https://secwatch.observer/filing/0000914475-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.